Sorted By Test Name - Mayo Medical Laboratories

QHCV
81130
while patients with chronic HCV genotype 1 and 4 infections receive a minimum of 48 weeks of
combination therapy if early virologic response is achieved. Therapeutic response rates for HCV genotype
1 infection are improved significantly (70%-80%) when a direct acting antiviral agent (eg, boceprevir,
telaprevir) is added to current standard combination therapy. However, antiviral resistance can emerge
during such combination therapy, and occurrence of such resistance is more frequent with HCV subtype
1a than 1b. See Advances in the Laboratory Diagnosis of Hepatitis C (2002) in Publications The
following algorithms are available in Special Instructions: -Recommended Approach to the Diagnosis of
Hepatitis C -Alternative Approaches to the Diagnosis of Hepatitis C -Chronic Hepatitis C
Standard-of-Care Treatment Algorithm: Combined Pegylated Interferon and Ribavirin Therapy -Chronic
Hepatitis C Treatment Algorithm: HCV Genotype 1 with Telaprevir-containing Combination Therapy
-Chronic Hepatitis C Treatment and Monitoring Algorithm: Boceprevir-Containing Combination Therapy
(HCV Genotype 1 only)
Useful For: Guiding duration of therapy in patients with chronic hepatitis C Differentiating between
hepatitis C virus subtypes 1a and 1b
Interpretation: An "Undetected" result indicates the absence of detectable hepatitis C virus (HCV)
RNA in the specimen. An "Indeterminate" result has the possible following causes: -Low HCV RNA
level (ie,